Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis.
Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.
Gilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors that could lead to cell therapies capable of targeting solid tumours.
